23 results about "Enterovirus Infections" patented technology

The present invention relates to an mRNA vaccine composition for the prevention of enterovirus A71 (EV-A71) infection. The composition comprises an mRNA encoding the VP1 protein of EV-A71 and lipid nanoparticles (LNPs) comprising specific cationic lipids. Compared with the conventional cationic lipid system, the imidazopyridyl cationic lipid A5 with strong membrane fusion capability is adopted, so that obvious neutralizing antibody and cellular immune response can be induced under single-time and low-dose immune conditions, and excellent safety and children applicability are shown.

The present disclosure relates to animal models that express human tryptophanyl-tRNA synthetase (hWARS) knock-in. These animal models are highly susceptible to enterovirus infection, including but not limited to EV-D68 and EV-A71 infection. Also disclosed are screening methods and compounds that utilize these animal models.

The invention relates to the field of medicines, and discloses application of doxazosin, thiobis (dichlorophenol) and diclophenol in preparation of medicines for preventing and / or treating enterovirus infection. The inventor finds that doxazosin mesylate, thiobichlorophenol and pharmaceutically acceptable salts or prodrugs thereof have a good inhibition effect on enteroviruses, especially poliovirus type 1, coxsackie virus group A type 9 and enterovirus type A71, and diclophenol has activity of resisting coxsackie virus. The method has an important clinical application value in treatment and prevention of related diseases caused by enterovirus infection.

The invention belongs to the technical field of antiviral polypeptides, and particularly relates to a broad-spectrum anti-enterovirus polypeptide and application thereof. The polypeptide for broad-spectrum inhibition of enterovirus infection is obtained and confirmed on the basis of virus experiments, the two linear polypeptides P11 and P25 are found to have the effect of inhibiting virus infection, and particularly, the effect of P25 is more stable.

The invention provides application of golden flower cold-clearing granules or active ingredients thereof in preparation of medicines for preventing, relieving and / or treating diseases caused by enterovirus infection. The golden flower cold-clearing granules and the effective components of the burdock phenol A and the 5, 7, 3 '-trihydroxy-6, 4', 5 '-trimethoxyflavone have good inhibitory activity on type 1 poliomyelitis virus, coxsackie virus group A type 9, enterovirus type 71, echovirus type 11 and coxsackie virus group B type 3, and the golden flower cold-clearing granules and the effective components of the burdock phenol A and the 5, 7, 3'-trihydroxy-6, 4 ', 5'-trimethoxyflavone have good inhibitory activity on type 1 poliomyelitis virus. Therefore, the golden flower cold-clearing granules or the effective components thereof have important clinical application value in treatment of diseases infected with enteroviruses.

The application discloses an oil and fat composition for resisting porcine enterovirus infection and application thereof. The oil and fat composition comprises at least two of glyceryl monopentanoate, glyceryl monolinoleate and glyceryl monomyristate. The oil and fat composition can further comprise anhydrous ethanol, propylene glycol, dimethyl sulfoxide, edible oil, Tween 80, lactose, mannitol, soluble starch, water and other auxiliary materials for preparing oil and fat composition preparations. The oil and fat composition can inhibit enterovirus through multiple channels and multiple levels, and improve the antiviral effect. Adding the oil and fat composition in the feed of pigs can not only improve the antiviral ability, but also reduce the inflammatory reaction caused by pathogenic infection through the anti-inflammatory and immune regulation effects, effectively prevent and treat the infection of porcine enterovirus diarrhea, and thus reduce the incidence of porcine enterovirus diarrhea and the mortality of pigs with the disease. The oil and fat composition can be used for preparing a medicine or a feed additive for treating and preventing porcine enterovirus diarrhea.

The present disclosure describes a method of treating a respiratory condition, wherein the respiratory condition is a respiratory enterovirus infection, an upper respiratory infection, a common cold, or a combination thereof, in a human subject with COPD which includes administering to the subject a therapeutically effective amount of vapendavir or a pharmaceutically acceptable salt thereof, thereby treating the respiratory condition in the subject. Pharmaceutical formulations of vapendavir and pharmaceutically acceptable salts thereof are also disclosed.

The invention provides an application of 27-hydroxycholesterol or pharmaceutically acceptable salt or ester thereof in preparation of a medicine for preventing and / or treating and / or relieving diseases and / or symptoms caused by enterovirus infection, and application of 27-hydroxycholesterol or pharmaceutically acceptable salt or ester thereof in preparation of a medicine for preventing and / or treating and / or relieving diseases and / or symptoms caused by enterovirus infection. And a method for non-therapeutic purposes of inhibiting enteroviruses in cells with at least one of 27-hydroxycholesterol or a pharmaceutically acceptable salt or ester thereof; the invention also provides an administration route and dosage form suitable for the medicament, other active ingredients which can be contained in the medicament, and a combination of the medicament and other medicaments.

This application provides an agent or a composition comprising viable cells or dead cells of the Lactobacillus plantarum strain (International Accession No. NITE BP-03418) as an active ingredient for preventing enteritis or necrotic enteritis, for suppressing inflammation due to enteritis or necrotic enteritis, for suppressing decreased feed conversion efficiency or body weight loss, or for suppressing infection with enteric viruses in a bird (for example, a chicken), or a method that comprises feeding a bird (for example, a chicken) with the agent or the composition.

The invention provides a broad-spectrum anti-enterovirus inhibitor imidazolone derivative as well as a preparation method and application thereof. A broad-spectrum anti-enterovirus inhibitor imidazolone derivative is successfully developed on the basis of a reasonable drug of a target structure, and particularly GT3 and HY7 are low-toxicity and efficient broad-spectrum anti-enterovirus (EV71, CVA6 and CVA10) drug molecules, so that novel drug candidate molecules are provided for treatment of enterovirus infection; important theoretical basis and technical support are also provided for development of broad-spectrum antiviral drugs, and important scientific significance and wide application prospects are achieved.

The application discloses a kind of compounds or its pharmaceutically acceptable salt, crystal form, solvate shown in formula I;Wherein, R1, R2, R3, R4 It is independently selected from halogen, C1~C4 Alkyl or halogen-substituted C1~C4 Alkyl.This kind of compound, it is connected by amido group with para-substituted phenyl and 3,5 position substituted benzyl to thiophene, novel and unique structure, to EV71, EVD68 Such as multiple enterovirus has good inhibitory activity and smaller cytotoxicity, provides a new potential choice for enterovirus infection with pharmacy drug.In addition, the application also discloses the preparation method and application of the compound shown in formula I, and its pharmaceutical composition.

The invention relates to the field of biological medicine, in particular to application of exosome miR-30e-5p and / or miR-34c-5p in detection of blood brain barrier damage and severe enterovirus infection. The exosome miR-30e-5p and / or miR-34c-5p provided by the invention is used as the marker, has high specificity and sensitivity in blood brain barrier damage detection, and can be used for early recognition of blood brain barrier damage and severe enterovirus infection. The invention proves that the miR-30e-5p and / or miR-34c-5p inhibitor reduces the permeability of the blood brain barrier by recovering the activity of the Notch pathway, and is expected to become a drug target for repairing structural damage, functional damage or inflammatory damage of the blood brain barrier.

[Solution] This disclosure describes a method for treating a respiratory enterovirus infection in a human subject having COPD, comprising the steps of: administering to the subject a therapeutically effective dose of bapendavir or a pharmaceutically acceptable salt thereof; and thereby treating the respiratory enterovirus infection in the subject. Pharmaceutical formulations of bapendavir are also disclosed.

This disclosure relates to nucleotide and nucleoside therapeutic compositions and uses in treating infectious diseases, viral infections, and cancer, where the base of the nucleotide or nucleoside contains at least one thiol, thione or thioether. The nucleotide and nucleoside therapeutic compositions can include at least one second antiviral agent, such as an antiviral agent that treats or prevents enterovirus infections.

The invention relates to the technical field of biological medicine, in particular to application of JAG-1 protein in preparation of medicine for treating enterovirus infection and repairing blood-brain barrier damage. The Notch-1 signal channel ligand protein JAG-1 provided by the invention can be used for treating enterovirus infection and repairing the integrity and selective permeability of a blood brain barrier by activating a Notch-1 signal channel. According to the invention, the JAG-1 protein is used for reducing viral load in the brain, relieving neurological illness related to damage of the blood-brain barrier and performing targeted treatment on the neurological illness, so that the severe death rate is reduced, complications are prevented, the treatment effect is improved, the treatment risk is reduced, and the life quality of a patient is improved.

The present disclosure provides a trefoil factor 2 (TFF2) / interferon α2 (IFNα2) fusion protein and an application thereof in prevention and treatment of viral infectious diseases. Specifically, the present disclosure provides a fusion protein, comprising: a TFF2 element containing a TFF2 peptide, and an IFNα2 element fused with the TFF2 element and containing an IFNα2 peptide. The present disclosure also provides an application of the fusion protein in prevention and / or treatment of viral infectious diseases (e.g., acute respiratory / enterovirus infections).

The invention discloses an application of masitinib, C22H17N3 and risedronic acid in preparation of a medicine for treating enterovirus infection. The invention discloses masitinib, C22H17N3, risedronic acid or derivatives thereof or pharmaceutically acceptable salts thereof or prodrugs thereof, or any one of the following applications of substances taking masitinib, C22H17N3, risedronic acid or derivatives thereof or pharmaceutically acceptable salts thereof as active ingredients in preparation of drugs for inhibiting enteroviruses; a2) a medicine for preventing and / or treating diseases caused by enterovirus infection; and A3) a medicine for improving symptoms caused by enterovirus infection. On the basis of an enterovirus type 71 and / or coxsackie virus drug screening model, an active drug masitinib capable of resisting enterovirus type 71, coxsackie virus group A type 9 and / or coxsackie virus group B type 3 is screened from listed drugs, and effect verification is carried out on a type 1 poliovirus model and / or an echovirus type 11 model.

Disclosed herein are synthetic peptides and compositions comprising the same for the treatment of enterovirus infection. Also disclosed herein are methods of treating enterovirus infection by administering to a subject in need of such treatment a composition containing an effective amount of a synthetic peptide of the present disclosure. In some cases, the subject is a human.

The present invention relates to the use of jujuboside B in the preparation of enterovirus inhibitors, belonging to the technical field of biopharmaceuticals. The main technical solutions are as follows: On the one hand, the present invention mainly provides the use of jujuboside B in the preparation of enterovirus inhibitors; on the other hand, the present invention provides an enterovirus inhibitor, the active ingredient of which is jujuboside B. The present invention mainly provides a potential drug with safety, high efficiency and low toxicity and side effects for the prevention or treatment of enterovirus infection.

In an aspect, the invention relates to compositions and methods for treating sepsis, including but not limited neonatal sepsis and sepsis related to infection. In an aspect, the invention relates to compositions and methods for attenuating adverse conditions of sepsis resulting from enterovirus infection. In an aspect, the invention relates to improved formulations of antiviral agents such as pleconaril for the treatment, alleviation and prevention of conditions associated with sepsis.

The invention belongs to the technical field of biological medicines, and particularly relates to an application of Shuanling antidiarrheal granules and clathrate compounds thereof in preparation of antiviral drugs. According to the invention, an enterovirus infected cell model is constructed, ribavirin is taken as a positive drug, and the in-vitro antiviral effects of the Shuangling antidiarrheal granules and the volatile oil inclusion compound of the Shuangling antidiarrheal granules are preliminarily evaluated. In particular, the virus comprises RVA and / or HastV. Researches prove that the Shuangporia and poria antidiarrheal granule dry extract powder and the volatile oil clathrate compound have remarkable antiviral activity on RVA and HastV in vitro, the inhibition effect of the Shuangporia and poria antidiarrheal granule dry extract powder on RVA is superior to that of the volatile oil clathrate compound, and the inhibition effect of the volatile oil clathrate compound on HastV is superior to that of the Shuangporia and poria antidiarrheal granule dry extract powder. The invention provides a scientific basis for the application of the Shuanling antidiarrheal granule dry extract powder and the volatile oil clathrate compound in the treatment of viral diarrhea.

This disclosure provides antibodies that bind enteroviruses. In some aspects, the disclosed antibodies bind and neutralize viruses from two or more clades of enterovirus. The disclosure also provides methods of using the disclosed antibodies to prevent infection of a cell with enterovirus, to protect an individual from enterovirus infection, and to treat an individual for an enterovirus infection.

The present invention discloses the use of ginsenoside Rg3 in the preparation of a drug for treating or preventing enteroviral infection, relating to the field of biomedicine. The ginsenoside Rg3 monomer in the present invention can enrich intestinal symbiotic bacteria. The short-chain fatty acids metabolites of the symbiotic bacteria enriched in this monomer, particularly acetic acid and propionic acid, have a strong antagonistic effect on enteroviral infection, improving the pathological damage caused by enteroviral infection, and is suitable for clinical promotion.